help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2005-0288
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Table
Right arrow All Versions of this Article:
20/2/291    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fowler, A. M.
Right arrow Articles by Alarid, E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fowler, A. M.
Right arrow Articles by Alarid, E. T.
Molecular Endocrinology 20 (2): 291-301
Copyright © 2006 by The Endocrine Society

Altered Target Gene Regulation Controlled by Estrogen Receptor-{alpha} Concentration

Amy M. Fowler, Natalia M. Solodin, Christopher C. Valley and Elaine T. Alarid

Department of Physiology, University of Wisconsin-Madison, Madison, Wisconsin 53706

Address all correspondence and requests for reprints to: Elaine T. Alarid, Ph.D., Department of Physiology, University of Wisconsin-Madison, 120 Service Memorial Institute, 1300 University Avenue, Madison, Wisconsin 53706. E-mail: alarid{at}physiology.wisc.edu.

Estrogen receptor-{alpha} (ER{alpha}) is a transcriptional activator whose concentration is tightly regulated by the cellular environment. In breast tumors of postmenopausal women, elevated receptor concentrations can be associated with negative clinical outcomes, yet it remains poorly understood how such high levels impact ER{alpha} function. We previously demonstrated that high nuclear concentrations of ER{alpha} in breast cancer cells bypass the requirement for ligand and are sufficient to activate transcription and accelerate proliferation. Here, we extended those studies and asked whether the transcriptional targets and activation mechanism are similar or different from that of estrogen-stimulated ER{alpha}. We found that at elevated levels, ER{alpha} activated, but could not repress, known estrogen-responsive genes. Moreover, the set of activated genes was expanded to include the uterine-restricted target gene, complement component 3. The activation mechanism of ER{alpha} under these conditions depends both on activation function-1 and residues in the proximal region of the ligand-binding domain. Mutations of aspartate 351 and leucine 372 can inhibit ER{alpha} transcriptional activity gained at high concentrations and discriminate concentration-inducible ER{alpha} function from that induced by estrogen. Moreover, we demonstrate that at high levels, ER{alpha} stimulates transcription without recruiting steroid receptor coactivator-3 and without interference by a Gal4-receptor interaction domain box fusion protein containing LxxLL motifs, further distinguishing this mode of regulation from known activation mechanisms. Together these results demonstrate that the concentration of receptor in breast cancer cells can influence the pattern of target gene expression through a noncanonical activation mechanism.

NURSA Molecule Pages Link:

Nuclear Receptors:   ERα  |  PR
Coregulators:   SRC-1  |  GRIP1  |  AIB1
Ligands:   17β-Estradiol



This article has been cited by other articles:


Home page
EndocrinologyHome page
X. Jiang, N. M. Patterson, Y. Ling, J. Xie, W. G. Helferich, and D. J. Shapiro
Low Concentrations of the Soy Phytoestrogen Genistein Induce Proteinase Inhibitor 9 and Block Killing of Breast Cancer Cells by Immune Cells
Endocrinology, November 1, 2008; 149(11): 5366 - 5373.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
W. Chen, T. Dang, R. D. Blind, Z. Wang, C. N. Cavasotto, A. B. Hittelman, I. Rogatsky, S. K. Logan, and M. J. Garabedian
Glucocorticoid Receptor Phosphorylation Differentially Affects Target Gene Expression
Mol. Endocrinol., August 1, 2008; 22(8): 1754 - 1766.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Mao, N. M. Patterson, M. T. Cherian, I. O. Aninye, C. Zhang, J. B. Montoya, J. Cheng, K. S. Putt, P. J. Hergenrother, E. M. Wilson, et al.
A New Small Molecule Inhibitor of Estrogen Receptor {alpha} Binding to Estrogen Response Elements Blocks Estrogen-dependent Growth of Cancer Cells
J. Biol. Chem., May 9, 2008; 283(19): 12819 - 12830.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
X. Li, S. L Nott, Y. Huang, R. Hilf, R. A Bambara, X. Qiu, A. Yakovlev, S. Welle, and M. Muyan
Gene expression profiling reveals that the regulation of estrogen-responsive element-independent genes by 17{beta}-estradiol-estrogen receptor {beta} is uncoupled from the induction of phenotypic changes in cell models
J. Mol. Endocrinol., May 1, 2008; 40(5): 211 - 229.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. D. Adamson, S. Friedrichsen, S. Semprini, C. V. Harper, J. J. Mullins, M. R. H. White, and J. R. E. Davis
Human Prolactin Gene Promoter Regulation by Estrogen: Convergence with Tumor Necrosis Factor-{alpha} Signaling
Endocrinology, February 1, 2008; 149(2): 687 - 694.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
C. C Valley, N. M Solodin, G. L Powers, S. J Ellison, and E. T Alarid
Temporal variation in estrogen receptor-{alpha} protein turnover in the presence of estrogen
J. Mol. Endocrinol., January 1, 2008; 40(1): 23 - 34.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Song and J. C. Fleet
Intestinal Resistance to 1,25 Dihydroxyvitamin D in Mice Heterozygous for the Vitamin D Receptor Knockout Allele
Endocrinology, March 1, 2007; 148(3): 1396 - 1402.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
B. Kuske, C. Naughton, K. Moore, K. G MacLeod, W. R Miller, R. Clarke, S. P Langdon, and D. A Cameron
Endocrine therapy resistance can be associated with high estrogen receptor {alpha} (ER{alpha}) expression and reduced ER{alpha} phosphorylation in breast cancer models
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1121 - 1133.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society